Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals-Reference-Cited by-同舟云学术

Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals

Published:2021-12-22 Issue:6 Volume:6 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Piscotta Frank J.¹,Hoffmann Hans-Heinrich²,Choi Young Joo³^ORCID,Small Gabriel I.³,Ashbrook Alison W.²,Koirala Bimal¹,Campbell Elizabeth A.³,Darst Seth A.³,Rice Charles M.²,Brady Sean F.¹

Affiliation:

1. Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA

2. Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA

3. Laboratory of Molecular Biophysics, The Rockefeller University, New York, New York, USA

Abstract

The continued prevalence of COVID-19 and the emergence of new variants has once again put the spotlight on the need for the identification of SARS-CoV-2 antivirals. The human microbiome produces an array of small molecules with bioactivities (e.g., host receptor ligands), but its ability to produce antiviral small molecules is relatively underexplored.

Funder

HHS | National Institutes of Health

G. Harold and Leila Y. Mathers Foundation

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mSphere.00711-21

Reference57 articles.

1. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021

2. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera